Literature DB >> 22389426

Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.

Terry W Moody1, Nauramy Osefo, Bernardo Nuche-Berenguer, Lisa Ridnour, David Wink, Robert T Jensen.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is an autocrine growth factor for some lung cancer cells. The activated PACAP receptor (PAC1) causes phosphatidylinositol turnover, elevates cAMP, and increases the proliferation of lung cancer cells. PAC1 and epidermal growth factor receptor (EGFR) are present in non-small-cell lung cancer (NSCLC) cells, and the growth of NSCLC cells is inhibited by the PAC1 antagonist PACAP(6-38) and the EGFR tyrosine kinase inhibitor gefitinib. Here, the ability of PACAP to transactivate the EGFR was investigated. Western blot analysis indicated that the addition of PACAP but not the structurally related vasoactive intestinal peptide increased EGFR tyrosine phosphorylation in NCI-H838 or H345 cells. PACAP-27, in a concentration-dependent manner, increased EGFR transactivation 4-fold 2 min after addition to NCI-H838 cells. The ability of 100 nM PACAP-27 to increase EGFR or extracellular signal-regulated kinase tyrosine phosphorylation in NCI-H838 cells was inhibited by PACAP(6-38), gefitinib, 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2; Src inhibitor), (R)-N4-hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide (GM6001; matrix metalloprotease inhibitor), or antibody to transforming growth factor α (TGFα). By enzyme-linked immunosorbent assay, PACAP addition to NCI-H838 cells increased TGFα secretion into conditioned media. EGFR transactivation caused by the addition of PACAP to NCI-H838 cells was inhibited by N-acetyl-cysteine (antioxidant), tiron (superoxide scavenger), diphenylene iodonium (NADPH oxidase inhibitor), or 1-[6-[[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122; phospholipase C inhibitor), but not N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide (H89; protein kinase A inhibitor). PACAP addition to NCI-H838 cells significantly increased reactive oxygen species, and the increase was inhibited by tiron. The results indicate that PACAP causes transactivation of the EGFR in NSCLC cells in an oxygen-dependent manner that involves phospholipase C but not protein kinase A.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22389426      PMCID: PMC3362890          DOI: 10.1124/jpet.111.190033

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.

Authors:  J C Reubi; U Läderach; B Waser; J O Gebbers; P Robberecht; J A Laissue
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

2.  Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells.

Authors:  A Miyata; A Arimura; R R Dahl; N Minamino; A Uehara; L Jiang; M D Culler; D H Coy
Journal:  Biochem Biophys Res Commun       Date:  1989-10-16       Impact factor: 3.575

3.  Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.

Authors:  Terry W Moody; Julius Leyton; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2011-09-06       Impact factor: 3.444

Review 4.  Neuropeptides as autocrine growth factors in cancer cells.

Authors:  Terry W Moody; Daniel Chan; Jan Fahrenkrug; Robert T Jensen
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.

Authors:  Qing Zhang; Sufi M Thomas; Sichuan Xi; Thomas E Smithgall; Jill M Siegfried; Joanne Kamens; William E Gooding; Jennifer Rubin Grandis
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

8.  Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor.

Authors:  Vivian Wai Yan Lui; Sufi Mary Thomas; Qing Zhang; Abbey Lynn Wentzel; Jill Marie Siegfried; Joyce Yan Li; Jennifer Rubin Grandis
Journal:  Oncogene       Date:  2003-09-18       Impact factor: 9.867

Review 9.  Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research.

Authors:  A Arimura
Journal:  Regul Pept       Date:  1992-02-18

10.  PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells.

Authors:  Terry W Moody; Julius Leyton; Marchessini Casibang; Joseph Pisegna; Robert T Jensen
Journal:  Regul Pept       Date:  2002-11-15
View more
  21 in total

1.  PACAP immunoreactivity in human malignant tumor samples and cardiac diseases.

Authors:  Z Szanto; Zs Sarszegi; D Reglodi; J Nemeth; K Szabadfi; P Kiss; A Varga; E Banki; K Csanaky; B Gaszner; O Pinter; Zs Szalai; A Tamas
Journal:  J Mol Neurosci       Date:  2012-05-31       Impact factor: 3.444

2.  PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells.

Authors:  Terry W Moody; Alessia Di Florio; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2012-05-12       Impact factor: 3.444

3.  Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Paula Moreno; Samuel A Mantey; Lisa Ridnour; David Wink; Robert T Jensen
Journal:  Peptides       Date:  2017-01-31       Impact factor: 3.750

Review 4.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

5.  Influence of terminal differentiation and PACAP on the cytokine, chemokine, and growth factor secretion of mammary epithelial cells.

Authors:  Katalin Csanaky; Wolfgang Doppler; Andrea Tamas; Krisztina Kovacs; Gabor Toth; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2013-12-10       Impact factor: 3.444

6.  CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Paola Moreno; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2015-03-12       Impact factor: 3.444

7.  PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Authors:  Terry W Moody; Lingaku Lee; Tatiana Iordanskaia; Irene Ramos-Alvarez; Paola Moreno; Howard E Boudreau; Thomas L Leto; Robert T Jensen
Journal:  Peptides       Date:  2018-09-28       Impact factor: 3.750

8.  Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.

Authors:  Alessia Di Florio; Veronica Sancho; Paola Moreno; Gianfranco Delle Fave; Robert T Jensen
Journal:  Biochim Biophys Acta       Date:  2012-12-04

9.  SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.

Authors:  Terry W Moody; Daniel C Chan; Samuel A Mantey; Paola Moreno; Robert T Jensen
Journal:  Life Sci       Date:  2014-02-02       Impact factor: 5.037

Review 10.  PACAP deficiency as a model of aging.

Authors:  D Reglodi; T Atlasz; E Szabo; A Jungling; A Tamas; T Juhasz; B D Fulop; A Bardosi
Journal:  Geroscience       Date:  2018-10-22       Impact factor: 7.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.